Invesfera Newsroom
Oral PCSK9: A Pill That Could Reshape Cholesterol Investing
The FDA approval of enlicitide marks a pivotal moment, introducing an oral PCSK9 inhibitor that challenges traditional treatments and opens new avenues for pharmaceutical investment.
